Here are seven articles published by Becker's Hospital Review in the last week, which highlight six regulatory decisions to watch for in September, Hospira's recall of two drugs and a supply chain tip for seasonal demand planning, among other topics.
- 6 FDA decisions to look for in September
The Food and Drug Administration has approved 31 new drugs so far in 2017, with a handful of regulatory decisions scheduled for this month, according to Zacks Investment Research.
- Novartis CEO to step down, hand over duties to drug development chief: 5 notes
Novartis, a Swiss pharmaceutical company, named its Global Head of Drug Development and CMO Vasant Narasimhan, MD, successor to current CEO Joe Jimenez, who will step down Jan. 31.
- Hospira recalls 2 drugs over sterility issues: 4 things to know
Hospira recalled one lot of Hydromorphone, a pain medication, and four lots of the blood pressure drug Levophed Thursday due to a potential lack of sterility assurance.
- Supply chain tip of the day: Consider seasonal indexes when demand planning
Flu season is coming and healthcare providers must prepare for its impact, according to Marie Fournier, director of business development and marketing for Montreal, Canada-based TECSYS.
- Patient death spurs FDA to halt cancer drug trials
The FDA placed a clinical hold on two of Collectis' clinical trials for an immunotherapy drug after a patient's death.
- Floridians urged to stock up on prescriptions before Hurricane Irma hits
Florida residents should refill prescription medications before Hurricane Irma hits the state, even if their current supply seems like an adequate amount, according to Candy McGuyre, corporate marketing director of Pensacola, Fla.-based Baptist Health Care.
- Eli Lilly to trim 8% of workforce: 4 things to know
Eli Lilly and Co. will lay off about 8 percent of its employees to cut costs in 2018.
More articles on supply chain:
Supply chain tip of the day: Consider seasonal indexes when demand planning
Hemophilia drug trial halted after patient death: 3 things to know
Novo Nordisk settles diabetes drug lawsuit for $58.7M: 3 things to know